Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

The absolute ... relative to the benchmmark, indicating that the company's earnings are more expensive than those of other companies in the index. A higher P/E, however, does not necessarily mean ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

Satish K. Garg “The [mean absolute relative difference] of 8% improves upon the accuracy of the current G7 of 8.2%; demonstrated high accuracy across wear periods, glucose concentrations and ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0% ...

With an overall Mean Absolute Relative Difference (MARD) of 8.0%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia ...